New immunosuppressants added

Two immunosuppressants have been added to the interaction checker. 
Filgotinib (Jyseleca®) is a JAK inhibitor indicated for the treatment of rheumatoid arthritis or ulcerative colitis. 
Risankizumab (Skyrizi®) is indicated for the treatment of plaque psoriasis and psoriatic arthritis, with an addition indication for active Crohn’s disease in the American product label.